多聚免疫球蛋白受体在肝细胞癌发病及诊治中的作用

张媛; 陈晓蓉; 杨宗国

doi:10.3969/j.issn.1001-5256.2020.07.043

多聚免疫球蛋白受体在肝细胞癌发病及诊治中的作用

DOI: 10.3969/j.issn.1001-5256.2020.07.043

1. 复旦大学附属公共卫生临床中心
2. 上海市公共卫生临床中心

基金项目:

国家自然科学基金项目(81803901)；上海市科委青年科技英才扬帆计划(17YF1416000)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 597
- HTML全文浏览量: 15
- PDF下载量: 149
- 被引次数: 0
出版历程
- 出版日期: 2020-07-20

Role of polymeric immunoglobulin receptor in the metastasis,growth,diagnosis,and treatment of hepatocellular carcinoma

1, 2. Shanghai Public Health Clinical Center Affiliated to Fudan University, Shanghai 201508, China

Research funding:

摘要

摘要:
肝脏慢性炎症是促进肝细胞癌发展的危险因素,在病毒感染的情况下,Fc受体信号加强也会进一步加重炎症反应,参与癌变的过程。多聚免疫球蛋白受体(pIgR)不仅在抗感染免疫第一线发挥至关重要的作用,在早期肝细胞癌的肿瘤转移和肿瘤生长中也发挥促进作用。将p IgR鉴定为早期肝癌患者转移潜能的预测指标可以有助于早期患者的分层和制订治疗决策,对改善患者预后具有积极意义。靶向抑制pIgR/Yes信号级联反应作为一种潜在的治疗方案可能会为控制肿瘤大小以允许切除或移植提供更多的治疗选择。
- 癌,肝细胞 /
- 多聚免疫球蛋白受体 /
- 受体,Fc /
- 肿瘤转移 /
- 生长 /
- 诊断
Abstract:
Chronic inflammation of the liver is a risk factor that promotes the progression of hepatocellular carcinoma,and in the presence of viral infection,enhanced Fc receptor signal will further aggravate inflammatory response and participate in the process of canceration. Polymeric immunoglobulin receptor( pIgR) not only plays a critical role in first-line anti-infection immunity,but also promotes the metastasis and growth of early-stage hepatocellular carcinoma. Identifying pIgR as a predictive index for metastatic potential in patients with early-stage liver cancer can help to promote the stratification and treatment decisions for such patients,which has a positive significance in improving patient prognosis. Targeted inhibition of the pIgR/Yes signal cascade as a potential treatment option may provide more treatment options for controlling tumor size to allow resection or transplantation.
- carcinoma,hepatocellular /
- polymeric immunoglobulin receptor /
- receptors,Fc /
- neoplasm metastasis /
- growth /
- diagnosis

HTML全文

参考文献(30)

[1]YANG JD,HAINAUT P,GORES GJ,et al.A global view of hepatocellular carcinoma:Trends,risk,prevention and management[J].Nat Rev Gastroenterol Hepatol,2019,16(10):589-604．

[2]HEIMBACH JK,KULIK LM,FINN RS,et al.AASLD guidelines for the treatment of hepatocellular carcinoma[J].Hepatology,2018,67(1):358-380．

[3]OMATA M,CHENG AL,KOKUDO N,et al.Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma:A2017 update[J].Hepatol Int,2017,11(4):317-370．

[4]DEWDNEY B,HEBBARD L.A novel role for polymeric immunoglobulin receptor in tumour development:Beyond mucosal immunity and into hepatic cancer cell transformation[J].Hepatobiliary Surg Nutr,2018,7(1):52-55．

[5]NIMMERJAHN F,RAVETCH JV.Fc-receptors as regulators of immunity[J].Adv Immunol,2007,96:179-204．

[6]ANDREU P,JOHANSSON M,AFFARA NI,et al.FcRgamma activation regulates inflammation-associated squamous carcinogenesis[J].Cancer Cell,2010,17(2):121-134．

[7]KAETZEL CS.The polymeric immunoglobulin receptor:Bridging innate and adaptive immune responses at mucosal surfaces[J].Immunol Rev,2005,206:83-99．

[8]TURULA H,WOBUS CE.The role of the polymeric immunoglobulin receptor and secretory immunoglobulins during mucosal infection and immunity[J].Viruses,2018,10(5):237．

[9]AI J,TANG Q,WU Y,et al.The role of polymeric immunoglobulin receptor in inflammation-induced tumor metastasis of human hepatocellular carcinoma[J].J Natl Cancer Inst,2011,103(22):1696-1712．

[10]YUE X,AI J,XU Y,et al.Polymeric immunoglobulin receptor promotes tumor growth in hepatocellular carcinoma[J].Hepatology,2017,65(6):1948-1962．

[11]TANG QJ,QI X,GENG MY.Important role of polymeric immunoglobulin receptor in mucosal immunity[J].Chin J Biochem Mol Biol,2007,23(9):724-729.(in Chinese)唐庆娟，戚欣，耿美玉．多聚免疫球蛋白受体(p IgR)在粘膜免疫中的重要功能[J]．中国生物化学与分子生物学报，2007,23(9):724-729．

[12]WEI HC.The bioinformatic research of PIGR and MYB gene family[D].Jinan:Shandong Normal University,2012.(in Chinese)魏海超．PIGR与MYB基因家族的生物信息学研究[D]．济南:山东师范大学，2012．

[13]ASANO M,KOMIYAMA K.Polymeric immunoglobulin receptor[J].J Oral Sci,2011,53(2):147-156．

[14]BERNTSSON J,LUNDGREN S,NODIN B,et al.Expression and prognostic significance of the polymeric immunoglobulin receptor in epithelial ovarian cancer[J].J Ovarian Res,2014,7:26．

[15]LIU F,YE P,BI T,et al.Colorectal polymeric immunoglobulin receptor expression is correlated with hepatic metastasis and poor prognosis in colon carcinoma patients with hepatic metastasis[J].Hepatogastroenterology,2014,61(131):652-659．

[16]KE QG,JIANG DQ,HUANG JC,et al.Clinical significance of polymeric immunoglobulin receptor in judging the recurrence and metastasis of liver cancer[J].Contemp Med,2014,20(11):92-93.(in Chinese)柯群刚，姜德清，黄继超，等．多聚免疫球蛋白受体在判断肝癌复发转移中的临床意义[J]．当代医学，2014,20(11):92-93．

[17]GIANNELLI G,KOUDELKOVA P,DITURI F,et al.Role of epithelial to mesenchymal transition in hepatocellular carcinoma[J].J Hepatol,2016,65(4):798-808．

[18]THIERY JP,ACLOQUE H,HUANG RY,et al.Epithelial-mesenchymal transitions in development and disease[J].Cell,2009,139(5):871-890．

[19]MANI SA,GUO W,LIAO MJ,et al.The epithelial-mesenchymal transition generates cells with properties of stem cells[J].Cell,2008,133(4):704-715．

[20]ANSIEAU S,BASTID J,DOREAU A,et al.Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence[J].Cancer Cell,2008,14(1):79-89．

[21]KUDO-SAITO C,SHIRAKO H,TAKEUCHI T,et al.Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells[J].Cancer Cell,2009,15(3):195-206．

[22]XU J,LAMOUILLE S,DERYNCK R.TGF-beta-induced epithelial to mesenchymal transition[J].Cell Res,2009,19(2):156-172．

[23]YANG Z,TAO Y,XU X,et al.Bufalin inhibits cell proliferation and migration of hepatocellular carcinoma cells via APOBEC3F induced intestinal immune network for Ig A production signaling pathway[J].Biochem Biophys Res Commun,2018,503(3):2124-2131．

[24]TORII S,YAMAMOTO T,TSUCHIYA Y,et al.ERK MAP kinase in G cell cycle progression and cancer[J].Cancer Sci,2006,97(8):697-702．

[25]CHANG F,STEELMAN LS,LEE JT,et al.Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors:Potential targeting for therapeutic intervention[J].Leukemia,2003,17(7):1263-1293．

[26]MCCUBREY JA,STEELMAN LS,CHAPPELL WH,et al.Roles of the Raf/MEK/ERK pathway in cell growth,malignant transformation and drug resistance[J].Biochim Biophys Acta,2007,1773(8):1263-1284．

[27] HANG JC,JIANG DQ,WANG ZS,et al.Role of plasma immunoglobulin receptor(PIgR/SC)in diagnosis of liver cancer[J].J Clin Psychos Dis,2016,22(z1):144-145.(in Chinese)黄继超，姜德清，王宗山，等．血浆多聚免疫球蛋白受体(PIgR/SC)对肝癌诊断的作用研究[J]．临床心身疾病杂志，2016,22(z1):144-145．

[28]TAN YH,SHANG YY,ZHANG T,et al.Current status and perspectives of multimodality therapy for hepatocellular carcinoma[J].J Clin Hepatol,2019,35(8):1858-1860.(in Chinese)谭运华，商阳阳，张涛，等．肝细胞癌综合治疗的现状和前景[J]．临床肝胆病杂志，2019,35(8):1858-1860．

[29]ZHENG WP,SHEN ZY.Risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma and related control strategies[J].J Clin Hepatol,2019,35(11):2391-2395.(in Chinese)郑卫萍，沈中阳．肝细胞癌肝移植术后肿瘤复发的危险因素与防治策略[J]．临床肝胆病杂志，2019,35(11):2391-2395．

[30]SAPISOCHIN G,BRUIX J.Liver transplantation for hepatocellular carcinoma:Outcomes and novel surgical approaches[J].Nat Rev Gastroenterol Hepatol,2017,14(4):203-217.

施引文献

资源附件(0)

访问统计